The Pharma Letter M&A roundup — March 2022

1 April 2022
skyscrapers_merger_stock_2022_large

An acquisition in the biosimilars space was the biggest deal announced in biopharma M&A during March.

Licensing agreements and other collaborations continue to account for most of the activity in the deal-making space as March mirrored February as a quiet month on the acquisitions front.

As well as Formycon's (LON: OW4N) purchase of biosimilar assets from ATHOS KG, acquisitions that were announced included the latest special purpose acquisition company (SPAC) deal and another buy by Fujifilm Holdings (TYO: 4901).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical